EGFR and Alzheimer disease: In our network pharmacology analysis, Mecasin was found to converge on several key nodes associated with neuroprotective processes, particularly AKT1, STAT3, and EGFR, suggesting that the formulation may engage molecular modules that support neuronal resilience in AD.